The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prognostic index model (PIM) for overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) without prior chemotherapy treated with abiraterone acetate (AA).
 
Charles J. Ryan
Honoraria - Astellas Pharma; Janssen Oncology
Consulting or Advisory Role - Bayer; Millennium
Research Funding - BIND Biosciences; Karyopharm Therapeutics; Novartis
 
Thian Kheoh
Employment - Janssen Research & Development
Leadership - Johnson & Johnson
Stock and Other Ownership Interests - Johnson & Johnson
 
Jinhui Li
Employment - Johnson & Johnson
Stock and Other Ownership Interests - Johnson & Johnson
 
Arturo Molina
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Johnson & Johnson
 
Peter De Porre
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Johnson & Johnson
 
Joan Carles
Honoraria - Astellas Pharma; Janssen; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Janssen; Sanofi
 
Eleni Efstathiou
Honoraria - Johnson & Johnson; Millennium; Sanofi
Consulting or Advisory Role - Johnson & Johnson; Millennium; Sanofi
Research Funding - Johnson & Johnson; Medivation; Millennium; Sanofi; Viamet Pharmaceuticals
 
Philip W. Kantoff
Stock and Other Ownership Interests - Bellicum Pharmaceuticals; BIND Biosciences; Blend Therapeutics; Metamark Genetics
Consulting or Advisory Role - Amgen; Aragon Pharmaceuticals; Archimedes; Astellas Pharma; Auven Therapeutics; Bavarian Nordic; Bayer; Bellicum Pharmaceuticals; BIND Biosciences; Blend Therapeutics; Celgene; Dendreon; Endocyte; Exelixis; Genomic Health; GTx; Janssen; Medivation; Merck; Metamark Genetics; Millennium; MorphoSys; MTG Therapeutics; OncoCellMDX; Oncogenex; Pfizer; Progenics; Roche; Sanofi; Sotio; Teva; Tokai Pharmaceuticals
Research Funding - Amgen (Inst); Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); Bavarian Nordic (Inst); Bayer (Inst); Dendreon (Inst); Exelixis (Inst); Janssen Oncology (Inst); Medivation (Inst); Oncogenex (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Bavarian Nordic; BIND Biosciences; Janssen; Millennium; Progenics; Sanofi
 
Peter F.A. Mulders
Honoraria - Astellas Pharma; Janssen; Novartis
Consulting or Advisory Role - Astellas Pharma; Janssen
Speakers' Bureau - Astellas Pharma; Janssen
Research Funding - Astellas Pharma; Bayer; Janssen
 
Fred Saad
Honoraria - Abbvie; Amgen; Astellas Pharma; Bayer; Janssen Oncology; Novartis; Sanofi
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; Bavarian Nordic; Janssen Oncology; Millennium; Novartis; Sanofi
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Oncogenex (Inst); Sanofi (Inst)
 
Thomas W. Griffin
Employment - Janssen Oncology
Stock and Other Ownership Interests - Janssen Oncology
 
Kim N. Chi
Honoraria - Astellas Pharma; Janssen; Sanofi
Consulting or Advisory Role - Amgen; Astellas Pharma; Bayer; ESSA; Janssen; Lilly/ImClone; Sanofi; Takeda
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Bayer (Inst); Exelixis (Inst); Janssen (Inst); Novartis (Inst); Oncogenex (Inst); Sanofi (Inst); Teva (Inst); Tokai Pharmaceuticals (Inst)